Genomic Opioid Optimization of Dosing and Selections (GOODS) Study
- Conditions
- Perioperative/Postoperative Complications
- Registration Number
- NCT03579121
- Lead Sponsor
- Mayo Clinic
- Brief Summary
The researchers are conducting this study to see if pharmacogenomic testing before surgery helps the doctor to choose which medications will work best for the patient.
- Detailed Description
Participants, undergoing total knee replacements, will be randomized into two groups. Both groups will receive pharmacogenomics (PGx) testing preoperatively. The PGx guided group will have their results reviewed by the clinicians during their treatment and the results may guide clinical decisions. The control group results will be sealed until completion of treatment and clinicians will not have access to this information. These participants will undergo standard treatment dosing and medication selection.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 76
- Patients undergoing primary total knee arthroplasty
- Patients must understand and provide written informed consent and HIPAA authorization prior to initiation of any study-specific procedures.
- Patients with a current diagnosis of chronic pain
- Patients requiring narcotics for greater than one week prior to surgery
- Patients with chronic kidney disease with a pre-op creatinine greater than 1.5
- Patient preference or need for spinal anesthesia rather than general anesthesia
- Patient planned for robotic surgical approach
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method Change in Overall Benefit of Analgesic Score (OBAS) baseline, 48 hours following PACU discharge The overall benefit of analgesia score (OBAS) is a daily multi-dimensional survey that assesses analgesia benefits, opioid-related adverse events (ORAEs), and patient satisfaction. It is a seven-item scale, with items ranging from( 0 = not at all) to(4 = very much). To calculate the Total OBAS score, compute the sum of scores in items 1-6 and add '4-score in item 7'. Low score indicates high benefit.
- Secondary Outcome Measures
Name Time Method Change in prescription pattern for postoperative pain control. baseline, 48 hours following PACU discharge Overall benefit of change in opioid prescription
Change in Opioid requirements baseline, 48 hours following PACU discharge Opioid doses will be recorded and converted into morphine equivalents.
Changes in opioid use perioperatively based on pharmacogenomic testing baseline, 48 hours following PACU discharge Opioid doses will be recorded and converted into morphine equivalents.
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
Trial Locations
- Locations (1)
Mayo Clinic in Arizona
🇺🇸Phoenix, Arizona, United States
Mayo Clinic in Arizona🇺🇸Phoenix, Arizona, United States